CeriBell (CBLL): Clarity Readings Linked to 3.6x Discharge Risk

CeriBell, Inc. (CBLL) told investors on its Q2 2026 earnings call, held August 10, 2026, that an independently published study for the first time linked seizure-burden readings from its Clarity algorithm to patients' clinical outcomes at hospital discharge — though the company still has not disclosed any revenue or usage figures tied specifically to that finding.[1]

What Clarity Does

CeriBell is a medical-technology company focused on acute neurological monitoring. Its core product is a bedside EEG system: clinical staff attach a portable electrode strip to a patient's scalp to capture brain-wave signals, and the company's Clarity algorithm analyzes that data in real time to determine whether the patient is having a seizure and to quantify how severe the seizure burden is, prompting the care team to decide whether to administer medication. The system is sold mainly to hospital intensive-care units and emergency departments, with customers paying on a per-case basis that produces recurring revenue. Clarity is not a peripheral add-on — it is the primary basis doctors use to decide whether and when to treat.

How the Application Evolved

The evidence trail for this application began with an earnings call on March 3, 2025, when management disclosed the technology had already been used on more than 200,000 patients since launch[2] and described an illustrative bedside case in which a patient's seizure resolved within an hour of treatment. Two months later, the company expanded the cleared indication from adults to patients aged one year and above, making Clarity the only FDA-cleared seizure-detection algorithm for that age range[3]. By November 2025, that pediatric expansion had supporting data: a retrospective study of 645 pediatric patients aged 1 to 17 reported 94.4% sensitivity, 93.1% specificity, and a 99.8% negative predictive value[4], moving the pediatric indication from cleared to pilot-validated. The August 10, 2026 disclosure is the latest step in that chain: it is the first time the company has linked Clarity's readings directly to patients' clinical outcomes at discharge.

The New Finding and Its Limits

The cited study found that when Clarity measured a peak seizure burden of 90% or greater, patients were 3.6 times more likely to experience severe disability or death at discharge; each additional hour of Clarity-detected seizure activity raised that risk by nearly two-fold. These figures describe a statistical association between the algorithm's readings and patient outcomes. Management cited an observational study without disclosing sample size, study design, or a control group that would isolate Clarity's own causal contribution to those outcomes.

What Would Have to Happen for This to Reach Revenue

If this deepening body of clinical evidence — from the sensitivity and specificity data to the newly cited outcome-linked study — leads hospitals to purchase faster, increases utilization within existing accounts, or accelerates commercialization of the pediatric and previously mentioned neonatal versions, it would in theory flow through to the portion of CeriBell's revenue tied to subscriptions and usage of this EEG monitoring system. But across all four earnings calls in this window, the company has not broken out usage volume, new account counts, or revenue specific to this system. The path from clinical evidence to revenue remains a plausible inference, not a number the company has verified.

Bottom Line

What is confirmed: CeriBell's Clarity bedside seizure-monitoring system has built an increasingly thick body of clinical evidence — from scaled adult use, to pediatric clearance and validation data, to a published study linking its readings to discharge outcomes. What is not yet confirmed: whether that evidence chain has translated into faster account penetration, larger pediatric volume, or any verifiable revenue metric. The next earnings call — if it discloses account counts, usage, or revenue tied to the pediatric or neonatal indications for the first time — will be the test.

Application Assessment

• Clarity Seizure Detection and Monitoring | Business position: core business | Deployment stage: limited production | Scope: multi-business/multi-region | Value type: risk reduction

Sources

[1] Drillr · CeriBell, Inc. (CBLL) · 2026-08-10 · Earnings call

"The study found that when our clarity algorithm reported a peak seizure burden of 90% or greater, patients were 3.6 times more likely to experience severe disability or death at discharge."

[2] Drillr · CeriBell, Inc. (CBLL) · 2025-03-03 · Earnings call

"To that end, I'm pleased to report that our technology has been now used on over 200,000 patients since we first launched."

[3] Drillr · CeriBell, Inc. (CBLL) · 2025-05-08 · Earnings call

"Clarity is now the first and only FDA-cleared seizure detection algorithm indicated for patients aged one year and above, thereby expanding our addressable patient population."

[4] Drillr · CeriBell, Inc. (CBLL) · 2025-11-04 · Earnings call

"The results demonstrated a sensitivity of 94.4% specificity of 93.1% and a negative predictive value of 99.8%."